Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trials Insight: 700023506

Trial Profile

Clinical Trials Insight: 700023506

Phase of Trial: Phase I

Latest Information Update: 31 Mar 2009

At a glance

  • Drugs ABT 107 (Primary)
  • Indications Cognition disorders
  • Focus Adverse reactions
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 31 Mar 2009 Status changed from recruiting to completed. Abbott has been evaluating ABT 107 under a license agreement with NeuroSearch. Based on results, Abbott and NeuroSearch have decided not to pursue development of the compound at this time.
    • 29 Nov 2007 Neurosearch report that the phase I programme is progressing as scheduled.
    • 31 May 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top